ArticleOncogene2003
FEV acts as a transcriptional repressor through its DNA-binding ETS domain and alanine-rich domain.
Article in Oncogene, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 43 citations in OpenAlex.
- [β-sitosterol, an important component in the fruits ofNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- The pivotal regulatory role of the FEV-SLC7A11 axis in ferroptosis elucidates the anti-aging mechanism of β-sitosterol in a cross-species study.Frontiers in pharmacology · 2025Article
- FEV-mediated WNT2 transcription is involved in the progression of colorectal cancer via the Wnt signaling.Cytotechnology · 2024Article
- Enhancer landscape of lung neuroendocrine tumors reveals regulatory and developmental signatures with potential theranostic implications.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Transcriptome analysis in a humanized mouse model of familial dysautonomia reveals tissue-specific gene expression disruption in the peripheral nervous system.Scientific reports · 2024Article
- RBFOX2 as a regulatory linchpin in cancer: insights from a comprehensive review of its roles in tumorigenesis.American journal of cancer research · 2024Review
- In-depth proteome analysis of brain tissue from Ewsr1 knockout mouse by multiplexed isobaric tandem mass tag labeling.Scientific reports · 2023Article
- Tumor Suppressor Role and Clinical Significance of theDisease markers · 2022Article
- Ewing sarcoma with FEV gene rearrangements is a rare subset with predilection for extraskeletal locations and aggressive behavior.Genes, chromosomes & cancer · 2020Article
- Comparative structure analysis of the ETSi domain of ERG3 and its complex with the E74 promoter DNA sequence.Acta crystallographica. Section F, Structural biology communications · 2018Article
- Serotonin neuron development: shaping molecular and structural identities.Wiley interdisciplinary reviews. Developmental biology · 2018Review
- Transposable elements are the primary source of novelty in primate gene regulation.Genome research · 2017Article
- Regulatory Mechanisms Controlling Maturation of Serotonin Neuron Identity and Function.Frontiers in cellular neuroscience · 2017Article
- Pet-1 Switches Transcriptional Targets Postnatally to Regulate Maturation of Serotonin Neuron Excitability.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2016Article
- The transcription factor Erg controls endothelial cell quiescence by repressing activity of nuclear factor (NF)-κB p65.The Journal of biological chemistry · 2012Article
- The expression of the transcription factor FEV in adult human brain and its association with affective disorders.Journal of neural transmission (Vienna, Austria : 1996) · 2010Article
- The 26S proteasome system degrades the ERM transcription factor and regulates its transcription-enhancing activity.Oncogene · 2007Article
- Regional distribution and cellular localization of the ETS-domain transcription factor, FEV, mRNA in the human postmortem brain.Synapse (New York, N.Y.) · 2005Article
- Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth.Oncogene · 2005Article
- Gfi/Pag-3/senseless zinc finger proteins: a unifying theme?Molecular and cellular biology · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although most Ets transcription factors have been characterized as transcriptional activators, some of them display repressor activity. Here we characterize an Ets-family member, the very specifically expressed human Fifth Ewing Variant (FEV), as a transcriptional repressor. We show that among a broad range of human cell lines, only Dami megakaryocytic cells express FEV. This nuclear protein binds to Ets-binding sites, such as that of the human ICAM-1 promoter. We used this promoter to demonstrate that FEV can repress both basal transcription and, even more strongly, ectopically Ets-activated transcription. We identified two domains responsible for FEV-mediated repression: the ETS domain, responsible for passive repression, and the carboxy-terminal alanine-rich domain, involved in active repression. In the Ets-independent LEXA system also, FEV acts as a transcriptional repressor via its alanine-rich carboxy-terminal domain. The mechanism by which FEV actively represses transcription is currently unknown, since FEV-triggered repression is not reversed by the histone deacetylase inhibitor trichostatin A. We also showed that long-term overexpression of FEV proteins containing the alanine-rich domain prevents cell clones from growing, whereas clones expressing a truncated FEV protein lacking this domain develop like control cells. This confirms the importance of this domain in FEV-triggered repression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.